Cases & Deals

  • Home
  • Practices
  • VST Bio establishes global patent portfolios related to anti-syndecan-2 antibodies for the treatment of diseases related to vascular permeability

Share

VST Bio establishes global patent portfolios related to anti-syndecan-2 antibodies for the treatment of diseases related to vascular permeability

April 2023

Client(s) VST Bio Corporation

Jones Day is representing VST Bio Corp. in connection with the establishment of a global patent portfolio related to antibodies that target syndecan-2 and uses thereof in the treatment of diseases related to vascular permeability and leakage, including ischemic stroke and myocardial infarction.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.